Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Illumina develops DNA sequencing, array-based, informatics and proteomics technologies for research, clinical and applied markets. Company news commonly covers sequencing instruments and consumables, NovaSeq X demand, DRAGEN software releases, TruPath Genome analytical support, and applications in oncology, reproductive health, agriculture, rare disease and drug discovery.
Illumina updates also include collaborations around precision oncology testing, preventive and population genomics, pediatric cancer and rare disease data, and the Alliance for Genomic Discovery. Financial and corporate news covers revenue trends, operating margins, earnings guidance, share repurchase authorizations, acquisitions in multiomics and proteomics, and board or management changes.
Illumina reported Q2 2022 revenue of $1.16 billion, a 3% increase year-over-year. However, the company faced a GAAP diluted loss per share of $(3.40), primarily due to $609 million in legal contingencies. Non-GAAP diluted EPS was $0.57, down from $1.87 in Q2 2021. For fiscal year 2022, revenue growth is expected at 4% to 5%, with anticipated GAAP diluted losses between $(2.93) and $(2.78). Despite revenue growth, ongoing legal issues and delays in customer lab expansions pose challenges.
Illumina (NASDAQ: ILMN) will host the Illumina Genomics Forum in San Diego from September 28 to October 1, featuring keynote speaker Bill Gates from the Bill & Melinda Gates Foundation. The forum will focus on achieving health equity through genomics and include a panel titled "Making 'Genomics for All' More than a Mantra." Additional discussions will explore how genomic technology can enhance patient care and support healthcare's quadruple aim. Other key speakers include former President Barack Obama, who will discuss healthcare equity and accessibility.
Illumina Ventures, in partnership with Illumina (NASDAQ: ILMN), strengthens its European operations by adding four new team members. The new hires include Arnaud Autret as Head of European Operations, William Byrne as an Associate, and Venture Advisors Ronan Byrne and Ivan Coulter. This expansion aims to bolster their focus on genomics-focused projects across Europe, enhancing their support for startups in clinical diagnostics and life sciences. The firm, dedicated to investing in innovative healthcare solutions, continues to pursue growth and transformation in the healthcare landscape.
Illumina has announced the launch of DRAGEN v4.0, a state-of-the-art secondary analysis platform designed to enhance genomic analysis accuracy and efficiency. This platform expands capabilities in oncology, pharmacogenomics, and population genomics, allowing for improved insights into genetic diseases and drug response. Noteworthy features include enhanced PGx capabilities, boosted whole-genome sequencing, and new single-cell pipelines. Illumina's commitment to innovation in genomics positions it as a leader in the industry.
Illumina (NASDAQ: ILMN) has announced its inaugural Illumina Genomics Forum, scheduled for September 28 to October 1, 2022, in San Diego, featuring former President Barack Obama in a moderated discussion on healthcare equity and accessibility. The Forum aims to bring together global leaders to discuss advancements in genomic technology for personalized healthcare and its applications in cancer and infectious disease treatment. The event emphasizes the importance of making genomic health an inclusive standard of care.
GRAIL announces that the NHS-Galleri trial has completed enrollment of 140,000 volunteers in just over 10 months. This trial, the largest of its kind, aims to assess the Galleri multi-cancer early detection test alongside standard screening in England. Participants aged 50-77 were recruited from diverse backgrounds to evaluate the test's ability to identify asymptomatic cancers earlier than current methods. The study supports the NHS's goal to catch 75% of cancers at an early stage, potentially rolling out the test to an additional 1 million people.
Illumina, Inc. (NASDAQ:ILMN) will announce its second quarter 2022 financial results after market close on August 11, 2022. A conference call will be held at 2:00 PM PT to discuss these results, featuring CEO Francis deSouza and CFO Joydeep Goswami. Investors can join via Illumina's website or by dialing in. The replay will be available for 30 days post-event. Illumina focuses on advancing healthcare through genomic solutions, catering to life sciences, clinical, and applied markets.
Summary not available.
Mercy and GRAIL have announced a partnership to offer the innovative Galleri blood test for multi-cancer early detection (MCED). This test identifies early cancer signals for over 50 cancer types, including aggressive types like pancreatic and ovarian cancers. Recommended for individuals at higher risk, such as those aged 50+, the test aims to complement existing cancer screening methods. Although not covered by insurance, Mercy will assist qualifying patients with costs. The Galleri test could significantly enhance early cancer detection and treatment prospects.
Community Health Network has partnered with GRAIL to become the first healthcare system in central Indiana to offer the Galleri multi-cancer early detection blood test. This initiative targets individuals at elevated risk for cancer, particularly those over 50, enhancing existing cancer screening protocols. The Galleri test can detect signals from over 50 cancer types and accurately predicts their origin, potentially improving early detection rates and patient outcomes. This collaboration reflects a commitment to advancing patient care and addressing the public health challenge of late cancer detection.